FONDAPARINUX SODIUM

Anticoagulant

Brand names: Fondaparinux Sodium

Subcutaneous

Mechanism of Action

12.1 Mechanism of Action The antithrombotic activity of fondaparinux sodium is the result of antithrombin III (ATIII)-mediated selective inhibition of Factor Xa. By selectively binding to ATIII, fondaparinux sodium potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII. Neutralization of Factor Xa interrupts the blood coagulation cascade and thus inhibits thrombin formation and thrombus development. Fondaparinux sodium does not inactivate thrombin (activated Factor II) and has no known effect on platelet function. At the recommended dose, fondaparinux sodium does not affect fibrinolytic activity or bleeding time.

Indications

hip replacement surgery

knee replacement surgery

or abdominal surgery. (1.1) Treatment of DVT or acute pulmonary embolism (PE) when administered in conjunction with warfarin. ( 1.2

1.3 ) 1.1 Prophylaxis of Deep Vein Thrombosis Fondaparinux sodium injection is indicated for the prophylaxis of deep vein thrombosis (DVT)

which may lead to pulmonary embolism (PE): in patients undergoing hip fracture surgery

including extended prophylaxis

Contraindications

• angioedema
• angioedema
• anaphylactoid/anaphylactic reactions) to fondaparinux sodium.

FDA Warnings

5 WARNINGS AND PRECAUTIONS Spinal or epidural hematomas, which may result in long-term or permanent paralysis, can occur ( 5
1 ) Patients taking fondaparinux sodium injection with risk factors for bleeding are at increased risk of hemorrhage
2 ) Bleeding risk is increased in renal impairment and in patients with low body weight 50 kg (5

Known Side Effects

5 documented side effects by frequency

Shortness of Breath

1-10%

Drug Not Working

1-10%

Fever

0.1-1%

Nausea

0.1-1%

Vomiting

0.1-1%

Community Discussions

No community discussions found for FONDAPARINUX SODIUM yet.

Compare With

4 available comparisons

Formulations

Dosage Forms

Tablet

Route

Subcutaneous